



# COALITION AGAINST SOCIALIZED MEDICINE

a Project of THE CONSERVATIVE POLITICAL ACTION COALITION

June 4, 2026

## Via Electronic Delivery

The Honorable Jim Jordan  
Chairman  
Committee on the Judiciary  
U.S. House of Representatives  
2138 Rayburn House Office Building  
Washington, D.C.20515

The Honorable Darrell Issa  
Chairman  
Subcommittee on Courts, Intellectual Property,  
Artificial Intelligence, and the Internet  
Committee  
on the Judiciary  
U.S. House of Representatives  
2138 Rayburn House Office Building  
Washington, D.C.20515

Dear Chairman Jordan, Chairman Issa, and Members of the Subcommittee on Courts, Intellectual Property, Artificial Intelligence, and the Internet Committee on the Judiciary:

The Coalition Against Socialized Medicine (CASM) thanks the Committee for holding the hearing, "[Medicines and IP: Balancing Innovation and Access.](#)" Intellectual property rights are a cornerstone of America's free market system and have helped make the United States the global leader in pharmaceutical innovation. Strong patent protections provide the certainty necessary to support the investment, research, and risk-taking required to develop tomorrow's medical breakthroughs.

As discussions around patents continue, false narratives surrounding so-called "patent gaming" persist, making troubling accusations about the legitimacy and necessity of IP protections in drug development. These claims often overlook both the realities of drug development and the safeguards already built into the patent system. In fact, a 2024 report from the United States Patent and Trademark Office (USPTO) found [no correlation](#) between the number of patents associated with a product and the length of market exclusivity.

The notion that pharmaceutical companies routinely use patents to improperly extend monopolies obscures the reality of medical innovation. Developing a new medicine is a costly, time-consuming, and risky endeavor. It typically takes a drug more than a decade and upwards of [\\$2 billion](#) to bring to market, with the vast majority of these drugs failing before ever reaching patients. Given the substantial

resources required to bring a single drug to market, patents are fundamental to the investment needed to develop new cures.

Importantly, the patent system already contains safeguards designed to prevent abuse. Every patent application is subject to rigorous review by the USPTO, whether it is brand-new or a modification of an existing medicine. In addition, closely related patents are often linked through terminal disclaimers, ensuring they expire simultaneously and prevent the artificial extension beyond the life of the original invention.

At a time when China is rapidly increasing its investment in its biotechnology and life sciences, weakening IP rights would threaten America's global leadership in medical innovation—leaving Americans with fewer treatment options and access barriers to essential medicines.

We strongly urge lawmakers to recognize that robust IP protections are essential to a thriving, free-market healthcare system. Strong patent frameworks incentivize innovation that brings life-changing treatments to patients, and without them, the pipeline of cutting-edge therapies that millions depend on would not exist.

Thank you for your time and attention to this matter.

Sincerely,

A handwritten signature in black ink that reads "Andrew M. Langer". The signature is written in a cursive, flowing style.

Andrew Langer  
Executive Director  
Coalition Against Socialized Medicine (CASM)